

This is an Open Access document downloaded from ORCA, Cardiff University's institutional repository: <https://orca.cardiff.ac.uk/id/eprint/137084/>

This is the author's version of a work that was submitted to / accepted for publication.

Citation for final published version:

Nishio Ayre, Wayne , Scully, Nicole, Elford, Carole, Evans, Bronwen AJ , Rowe, Wendy, Rowlands, Jeff, Mitha, Ravi, Malpas, Paul, Manti, Panagiota, Holt, Cathy , Morgan-Jones, Rhidian, Birchall, James , Denyer, Stephen P and Evans, Sam L 2021. Alternative radiopacifiers for polymethyl methacrylate bone cements: Silane-treated anatase titanium dioxide and yttria-stabilised zirconium dioxide. *Journal of Biomaterials Applications* 35 (10) , pp. 1235-1252. 10.1177/0885328220983797

Publishers page: <http://dx.doi.org/10.1177/0885328220983797>

Please note:

Changes made as a result of publishing processes such as copy-editing, formatting and page numbers may not be reflected in this version. For the definitive version of this publication, please refer to the published source. You are advised to consult the publisher's version if you wish to cite this paper.

This version is being made available in accordance with publisher policies. See <http://orca.cf.ac.uk/policies.html> for usage policies. Copyright and moral rights for publications made available in ORCA are retained by the copyright holders.



# Alternative radiopacifiers for polymethyl methacrylate bone cements: Silane-treated anatase titanium dioxide and yttria-stabilised zirconium dioxide

Journal of Biomaterials Applications

2021, Vol. 35(10) 1235–1252

© The Author(s) 2021




Article reuse guidelines:

[sagepub.com/journals-permissions](https://sagepub.com/journals-permissions)

DOI: 10.1177/0885328220983797

[journals.sagepub.com/home/jba](https://journals.sagepub.com/home/jba)

Wayne Nishio Ayre<sup>1</sup> , Nicole Scully<sup>2</sup>, Carole Elford<sup>2</sup>,  
Bronwen AJ Evans<sup>2</sup>, Wendy Rowe<sup>1</sup>, Jeff Rowlands<sup>3</sup>,  
Ravi Mitha<sup>3</sup>, Paul Malpas<sup>3</sup>, Panagiota Manti<sup>4</sup>, Cathy Holt<sup>3</sup>,  
Rhidian Morgan-Jones<sup>5</sup>, James C Birchall<sup>6</sup>,  
Stephen P Denyer<sup>7</sup> and Sam L Evans<sup>3</sup>

## Abstract

Poly (methyl methacrylate) (PMMA) bone cement is widely used for anchoring joint arthroplasties. In cement brands approved for these procedures, micron-sized particles (usually barium sulphate, BaSO<sub>4</sub>) act as the radiopacifier. It has been postulated that these particles act as sites for crack initiation and subsequently cement fatigue. This study investigated whether alternative radiopacifiers, anatase titanium dioxide (TiO<sub>2</sub>) and yttria-stabilised zirconium dioxide (ZrO<sub>2</sub>), could improve the *in vitro* mechanical, fatigue crack propagation and biological properties of polymethyl methacrylate (PMMA) bone cement and whether their coating with a silane could further enhance cement performance. Cement samples containing 0, 5, 10, 15, 20 and 25%w/w TiO<sub>2</sub> or ZrO<sub>2</sub> and 10%w/w silane-treated TiO<sub>2</sub> or ZrO<sub>2</sub> were prepared and characterised *in vitro* in terms of radiopacity, compressive and bending strength, bending modulus, fatigue crack propagation, hydroxyapatite forming ability and MC3T3-E1 cell attachment and viability. Cement samples with greater than 10%w/w TiO<sub>2</sub> and ZrO<sub>2</sub> had a similar radiopacity to the control 10%w/w BaSO<sub>4</sub> cement and commercial products. The addition of TiO<sub>2</sub> and ZrO<sub>2</sub> to bone cement reduced the bending strength and fracture toughness and increased fatigue crack propagation due to the formation of agglomerations and voids. Silane treating TiO<sub>2</sub> reversed this effect, enhancing the dispersion and adhesion of particles to the PMMA matrix and resulted in improved mechanical properties and fatigue crack propagation resistance. Silane-treated TiO<sub>2</sub> cements had increased nucleation of hydroxyapatite and MC3T3-E1 cell attachment *in vitro*, without significantly compromising cell viability. This research has demonstrated that 10%w/w silane-treated anatase TiO<sub>2</sub> is a promising alternative radiopacifier for PMMA bone cement offering additional benefits over conventional BaSO<sub>4</sub> radiopacifiers.

## Keywords

PMMA, bone cement, radiopacifier, silane, mechanical, biocompatibility, toxicity

## Introduction

Polymethyl methacrylate (PMMA) bone cement was first introduced into orthopaedic surgery in the late 1950s when Sir John Charnley used the material to successfully anchor a hip replacement to bone.<sup>1</sup> This

procedure has since grown in popularity, with recent data from the National Joint Registry (for England,

<sup>1</sup>School of Dentistry, Cardiff University, Cardiff, UK

<sup>2</sup>School of Medicine, Cardiff University, Cardiff, UK

<sup>3</sup>School of Engineering, Cardiff University, Cardiff, UK

<sup>4</sup>School of Environment, Ionian University, Zakynthos, Greece

<sup>5</sup>Department of Trauma & Orthopaedics, Cardiff & Vale University Health Board, Cardiff, UK

<sup>6</sup>School of Pharmacy and Pharmaceutical Sciences, Cardiff University, Cardiff, UK

<sup>7</sup>School of Pharmacy and Biomolecular Sciences, University of Brighton, Brighton, UK

## Corresponding author:

Wayne Nishio Ayre, Cardiff University, Heath Park, Cardiff, South Glamorgan CF14 4XY, UK.

Email: [ayrewn@cardiff.ac.uk](mailto:ayrewn@cardiff.ac.uk)

Wales, Northern Ireland, the Isle of Man and the States of Guernsey) indicating in 2018, approximately 28% of primary hip procedures and 86% of primary knee procedures used PMMA bone cement.<sup>2</sup> PMMA has also shown promise for other biomedical applications, such as tissue engineering,<sup>3–5</sup> and as a vehicle for delivering a wide range of therapeutics.<sup>6–9</sup> Although joint replacements are considered to be one of the most successful surgeries of the 20<sup>th</sup> century, data from the National Joint Registry has shown that approximately 14,920 revision surgeries were performed in 2018 for failed hip and knee replacements (7% of all hip and knee procedures), with aseptic loosening being the major cause of failure, accounting for approximately 40% of revisions.<sup>2</sup>

As the probability of aseptic loosening in cemented joint replacements increases over time, cement fatigue is likely involved in the failure process.<sup>2,10</sup> Although the shape and surface texture of implants have been optimised to improve the distribution of stresses across the cement mantle,<sup>11–13</sup> internal stress concentrations within the cement still arise from pores, voids and radiopacifier agglomerations.<sup>14–20</sup> Retrieval studies have shown these stress concentrations to initiate fatigue cracks with subsequent cyclic loading and overloads causing these cracks to propagate and coalesce over prolonged periods of time.<sup>21,22</sup> This gradually weakens the cement, resulting in fatigue failure below the maximum strength of the material.<sup>23</sup>


As PMMA does not effectively attenuate X-rays, radiopacifiers, such as micron-sized barium sulphate ( $\text{BaSO}_4$ ) particles, have been approved for commercial bone cements. The addition of inorganic particles (8–15% w/w of the powdered component) allows the location, penetration and integrity of the cement to be observed non-invasively using X-ray imaging. The effect of radiopacifiers on the mechanical and fatigue crack growth rates of PMMA bone cement has been widely researched. Baleani and Viceconti<sup>24</sup> showed that adding 10% w/w  $\text{BaSO}_4$  to PMMA lowered the endurance limit and fracture toughness of the material by 13% but also decreased the crack growth rate by up to 66%. A study by Ginebra et al.<sup>25</sup> found that  $\text{BaSO}_4$  decreased the tensile strength but improved the crack propagation resistance of PMMA. Lewis<sup>10</sup> highlighted the positive effect radiopacifiers can have in reducing crack propagation by drawing on 6 different studies.<sup>26–31</sup> It was hypothesised that inorganic filler particles delay crack propagation by redirecting and deviating the crack tip. Conversely, other studies have shown agglomerations of radiopacifiers to be detrimental to the fatigue life of the cement.<sup>16–20</sup> These studies showed agglomerations to act as sites for crack initiation, with debonding of the radiopacifier from the PMMA matrix also creating defects in the material.<sup>15–20</sup> An analytical

study using stress analysis and fracture mechanics by Evans<sup>32</sup> also found that large defects, such as those caused by agglomerations, can cause a disproportionate increase in crack growth rates. Therefore, although radiopacifiers have been shown to reduce crack propagation, large agglomerates are also thought to be a source for crack initiation and a disproportionate increase in crack growth.

An additional area of concern surrounding the radiopacifiers used in bone cements is the potential effect on osteolysis and bone resorption. *In vitro* studies have shown wear debris and radiopacifier particles from PMMA bone cement induced high levels of inflammatory cytokine production from monocytes and enhanced osteoclast differentiation.<sup>33–35</sup> *In vivo* rat tibial implantation and subcutaneous pouch studies have confirmed similar findings.<sup>34,36</sup> These studies have also shown  $\text{BaSO}_4$  radiopacifiers to be more detrimental than PMMA particles or  $\text{ZrO}_2$  radiopacifiers, inducing higher levels of inflammation and bone resorption.<sup>35,36</sup> To overcome these issues, focus has been placed on the development of iodine-based radiopacifiers and nano-sized radiopacifiers;<sup>37–39</sup> however concerns regarding allergic reactions to iodine and the potential systemic effects of nanoparticles have limited their clinical translation.<sup>40,41</sup>

The use of alternative micron-sized radiopacifiers with unique material properties may help overcome some of the issues previously outlined. Yttria-stabilised  $\text{ZrO}_2$  for example, has unique transformation toughening mechanisms. When heated above 950 °C, the crystal structure of  $\text{ZrO}_2$  converts to a tetragonal arrangement which is accompanied by a 1–4% volumetric reduction.<sup>42</sup> Addition of stabilisers such as yttria helps maintain this crystal structure upon cooling. When a crack tip approaches the yttria-stabilised  $\text{ZrO}_2$ , the tetragonal crystal structure reverts to a monoclinic phase and due to its increase in volume, applies compression to the crack tip, slowing crack growth.<sup>42</sup> Other materials such as titanium dioxide ( $\text{TiO}_2$ ) may offer alternative benefits such as increased calcium ion interaction, which is important for protein and osteoblast attachment as well as hydroxyapatite (HA) formation.<sup>43</sup> The anatase crystal structure of  $\text{TiO}_2$  is speculated to have a higher bioactivity than rutile or amorphous  $\text{TiO}_2$  due to the closer lattice match with HA, higher acidity and lower surface zeta potential caused by a larger number of surface hydroxyl groups.<sup>44,45</sup> Deposition of HA on anatase at a pH of 7.4 has been shown to be faster than on the rutile form at the same pH.<sup>44</sup>

Chemically modifying the surface of the radiopacifier may also prevent agglomerations and debonding from the PMMA matrix. For example, silane coupling agents (herein referred to as silanes) can be used to modify the wetting and adhesion characteristics of



**Figure 1.** (a) General structure of silanes; (b) the hydrolytic deposition of silanes on substrates; and (c) the chemical structure of methacryloxypropyltrimethoxysilane (MPS).

substrates and can create chemical bonds between organic and inorganic materials. Silanes are composed of an organofunctional group, a linker, a silicon atom and a hydrolyzable group (Figure 1(a)).<sup>46</sup> The functional group ( $R$  group) mediates interactions with other materials and the length of the linker allows the functional group to extend farther from the inorganic substrate to improve particle dispersion characteristics.<sup>47</sup> Silane functionalisation of surfaces occurs in four sequential steps (Figure 1(b)): (1) hydrolysis of the 3 labile groups; (2) condensation of the oligomers; (3) hydrogen bonding of the oligomers with hydroxyl groups on the substrate surface; and (4) covalent bonding with the substrate during drying/curing.<sup>47</sup> The radiopacifiers previously discussed ( $TiO_2$  and  $ZrO_2$ ) both have hydrolytically stable surface oxides with sufficient hydroxyl functionality to allow coupling by the hydrolytic deposition process outlined.

The aim of the present study was to assess the suitability of anatase titanium dioxide ( $TiO_2$ ) and yttria-stabilised zirconium dioxide ( $ZrO_2$ ), as alternative radiopacifiers for PMMA bone cement, over conventional  $BaSO_4$  radiopacifier particles. The study also

investigated whether silane treatment of these alternative radiopacifiers can further enhance *in vitro* mechanical, fatigue crack propagation and biological cement performance. Two commercial brands of cement, widely used in anchoring joint arthroplasties (Cemex Isoplastic and Palacos R), were also included in this study as reference materials for the clinically relevant properties studied.

## Materials and methods

### Materials

Anatase  $TiO_2$ , yttria-stabilised  $ZrO_2$ , methyl methacrylate with 75 ppm hydroquinone, N-N dimethyl-p-toluidine, benzoyl peroxide and methacryloxypropyltrimethoxysilane were purchased from Sigma Aldrich (Gillingham, UK).  $BaSO_4$  and Whatman grade 6 filters (185 mm diameter) were purchased from Fisher Scientific UK (Leicestershire, UK). Polymethyl methacrylate powder with a methylacrylate copolymer (Colacryl TS1713) was kindly provided by Lucite International UK (Southampton, UK). Cemex



Isoplastic, which contains BaSO<sub>4</sub> as a radiopacifier, was kindly provided by Tecres (Sommacampagna, Italy) and Palacos R, which contains ZrO<sub>2</sub> that is not yttria-stabilised as a radiopacifier, was kindly provided by Heraeus (Newbury, UK). Alpha Minimum Essential Medium ( $\alpha$ -MEM with nucleosides, L-glutamine, sodium pyruvate, lipoic acid, B12, biotin and ascorbic acid), foetal bovine serum and penicillin/streptomycin were purchased from Life Technologies Ltd (Paisley, UK).

### Particle size of radiopacifiers

The particle size distributions of BaSO<sub>4</sub>, anatase TiO<sub>2</sub> and yttria-stabilised ZrO<sub>2</sub> were examined using laser diffraction (Mastersizer X, Malvern Instruments Ltd, Worcestershire, UK) attached to an ultrasonic bath mixer. 1 g of the radiopacifier was added to 50 mL deionised distilled water in the ultrasonic bath mixer. This disperses the particles, preventing agglomerations in order to obtain accurate size readings. The suspension was measured using a 45 mm optical lens.

### Silane treatment

The silane coating procedure was based on industrial processes used to coat metallic surfaces and glassware.<sup>46,48</sup> A 100 mL solution of 95%v/v ethanol was prepared and the pH adjusted to 4.5–5.5 using acetic acid. Methacryloxypropyltrimethoxysilane (MPS, also known as 3-(trimethoxysilyl)propyl methacrylate) was added at a 2%v/v concentration and allowed to hydrolyse at room temperature for 5 minutes. MPS was selected for this study as it has been previously used as an implant coating to enhance adherence to bone cements.<sup>49,50</sup> This silane has three carbon atoms between the functional group and the silicon atom (Figure 1(c)). It is a gamma substituted silane, which is thermally stable up to 350 °C short-term and 160 °C long-term and will not be affected by the exothermic polymerisation reaction of bone cement and the temperatures experienced *in vivo*. MPS also has a similar reported toxicity to methyl methacrylate (LD50 > 3000 mg/kg).<sup>46</sup> 5 g of radiopacifier powder (anatase TiO<sub>2</sub> or yttria-stabilised ZrO<sub>2</sub>) was added to the solution and stirred for 24 hours at 25 °C. The suspension was allowed to settle and the upper clear solution decanted. The remaining slurry was filtered through a Whatman grade 6 filter. The slurry was rinsed twice with ethanol to remove excess unreacted silane before drying at 80 °C for 24 hours. Once dried, the powder was crushed using a pestle and mortar and passed through a 30-mesh sieve followed by a 300-mesh sieve to ensure a powder size of less than 50  $\mu$ m.

### Fourier transform infrared spectroscopy of silane-treated radiopacifiers

To evaluate the success of the treatment process, Fourier Transform Infrared Spectroscopy (FT-IR) measurements were taken in transmission between 4000 cm<sup>-1</sup> and 450 cm<sup>-1</sup> with a resolution of 4 cm<sup>-1</sup> using a Perkin Elmer Spectrum One FT-IR Spectrometer with FT-IR Spectrum software (Perkin Elmer, Massachusetts, USA). Potassium bromide (KBr) discs were prepared by combining 1 mg of the sample (MPS, TiO<sub>2</sub>, ZrO<sub>2</sub> or silane-treated TiO<sub>2</sub> and ZrO<sub>2</sub>) with 100 mg of potassium bromide (KBr) using a pestle and mortar until a fine uniform powder was obtained. The powder was then placed between two stainless steel disks and subjected to a force of 10 kN for 30 seconds, followed by 100 kN for a further 30 seconds to create discs. Two discs were prepared per sample and 30 scans per sample were performed to obtain an averaged spectrum.

### Cement preparation

The ISO5833:2002 (Implants for surgery - Acrylic resin cements) standard was used as a guideline for preparing cement samples, to ensure consistency between mixing batches.<sup>51</sup> All the contents of the cement were equilibrated in air at 23 °C for 2 hours prior to mixing. Cement components were weighed and combined as outlined in Table 1. Samples were prepared containing 0, 5, 10, 15, 20 and 25%w/w of untreated TiO<sub>2</sub> or ZrO<sub>2</sub> and 10%w/w silane-treated TiO<sub>2</sub> or ZrO<sub>2</sub>. Due to the differences in composition and manufacturing methods between the commercial and the formulated cements, samples containing 10%w/w BaSO<sub>4</sub> were also prepared to establish the effect of the alternative radiopacifiers alone. Each powdered component was passed through a 35-mesh sieve (0.5 mm opening) before being weighed to an accuracy of  $\pm 0.01$  g and blended together. Separately, each ingredient of the liquid component was weighed and mixed together. Both components were then introduced into a clean polypropylene bowl and hand-mixed at approximately 1 Hz with a polypropylene spatula for 1 minute. The mixture was then poured into a polytetrafluoroethylene (PTFE) mould to either polymerise for 24 hours or to measure the setting properties. Two commercially available bone cements (Cemex Isoplastic and Palacos R) were also mixed according to manufacturer's instructions to act as reference materials. Following mixing and curing, surfaces were visually inspected and samples containing large pores (>0.5 mm) were discarded. Similarly, the results from samples with large pores in the fracture surfaces were discarded and additional samples tested.

**Table 1.** Composition of tested bone cements.

		Cemex isoplastic	Palacos R		Test samples				
Liquid	Total liquid (g)	13.3	18.8		16.9				
	Methyl methacrylate (%w/w)	99.1	98.0		98.5				
	N-N dimethyl-p-toluidine (%w/w)	0.9	2.0		1.5				
	Hydroquinone(ppm)	75.0	60.0		75.0				
Powder	Total powder (g)	40.0							
	Polymethyl methacrylate (%w/w)	84.3	84.5 <sup>a</sup>	98.3	93.3	88.3	83.3	78.3	73.3
	Radiopacifier(%w/w)	13.0	15.0	0.0	5.0	10.0	15.0	20.0	25.0
	Benzoyl peroxide(%w/w)	2.7	0.5	1.7	1.7	1.7	1.70	1.7	1.7
Powder:liquid ratio		3.0	2.1		2.4				

<sup>a</sup>Poly(methyl methacrylate/methyl acrylate) powder.

### Radiopacity

To assess whether the alternative radiopacifiers provided similar radiopacity to BaSO<sub>4</sub> containing cements and commercial products, radiographic images of 2 mm × 10 mm square cement samples were captured using a Kodak *in vivo* Imaging System FX Pro (Kodak Molecular Imaging™ Systems, USA) using an accelerating voltage of 35 kVp, 150 μA. The dimensions were selected to represent the minimum cement mantle thickness found *in vivo*.<sup>52</sup> Images were acquired using Kodak Molecular Imaging™ V3 software and analysed using ImageJ (National Institutes of Health, Maryland, USA) to assess the optical density of samples in terms of average brightness of the image picture elements (pixels). The results were obtained as mean grey values, ranging from 0 (black) to 255 (white). A mean grey value of 255 would indicate complete absorption of X-rays, whilst a value of 0 would indicate complete transmission. Two samples for each test group were measured in air.

### Setting time and temperature

To ensure the setting time and temperature of the bone cements were not drastically altered by the alternative radiopacifiers, measurements and calculations for the setting properties were carried out according to the ISO5833:2002 standard using a high-density polyethylene mould and a K-type wire thermocouple connected to a Picotech ADC11 Data Logger (Cambridgeshire, UK).<sup>51</sup> The ambient temperature was recorded prior to mixing and 25 g of cement was prepared as previously described. Temperature and time recording started when the liquid came into contact with the powder. Temperatures were recorded to an accuracy of ±0.5 °C. The setting temperature was calculated as the mean of the maximum setting temperature and the ambient temperature. The setting time was defined as the time when the setting temperature was reached.

### Surface energy

To investigate whether properties of the alternative radiopacifiers influenced the bulk hydrophilicity of the bone cement, surface energy measurements were performed according to the EN828 British Standards method.<sup>53</sup> Small cylindrical bone cement samples (10 mm diameter, 2 mm thickness) containing 10% w/w BaSO<sub>4</sub>, TiO<sub>2</sub>, ZrO<sub>2</sub>, silane-treated TiO<sub>2</sub> and silane-treated ZrO<sub>2</sub> were prepared as previously described. The flat surfaces of the samples were polished with a 500-grit silicon carbide paper. Three test liquids were used in this experiment: water, methanol and glycerol. 2 μL of the test liquid was pipetted perpendicularly onto the surface of the sample and an image was taken of the profile of the droplet using a high definition digital camera. The images were then imported into ImageJ (National Institutes of Health, Maryland, USA) and the advancing and receding contact angles measured to give an average contact angle per sample (θ). Five samples were tested per group. A linear variation ( $y = mx + c$ ) of Young's equation was used to calculate the total surface free energy of each sample. The interfacial tension values for the test liquids and the average contact angles for each liquid on a sample were used to calculate the surface free energy as outlined in the EN828 British Standards.<sup>53</sup>

### Compressive and bending properties

Compression and bending properties were determined using a Zwick Roell ProLine table-top Z050/Z100 materials testing machine with TestXpert II software (Zwick Testing Machines Ltd., Herefordshire, UK) following the ISO5833 standard to investigate the effect of the alternative radiopacifiers on the mechanical performance of the cement.<sup>51</sup> Cylindrical compression samples (6 mm diameter and 12 mm height) were tested at a cross-head speed of 20 mm/min. Rectangular bending samples (75 mm length, 10 mm width and 3.3 mm thickness) were tested at a cross-head speed of 5 mm/min in four-point bending. Five compression and five bending

samples were tested to determine average compression and bending properties.

### Fracture toughness

Linear elastic fracture mechanics tests using single-edge notched three-point bending samples (35 mm length, 10 mm width and 3 mm thickness) were used to determine changes in the fracture toughness due to the different radiopacifiers. A sharp chevron notch (4.5 to 5.5 mm in length) was created through the centre of the sample using a surgical scalpel blade mounted onto a modified microtome, as described by Evans<sup>23</sup> and the initial crack length and specimen dimensions measured using a travelling microscope (Pye Scientific, Cambridge, UK). The specimens were loaded at a crosshead speed of 5 mm/min in three-point bending, with the span between the rollers set to 40 mm, until failure occurred. The load and displacement were recorded and the critical stress intensity factor ( $K_{ic}$ ) of the cement was calculated as described in the ISO13586:2000 standard and in previous studies.<sup>6,54,55</sup> Five samples were tested for each group to produce mean fracture toughness values.

### Fatigue crack growth rates

To accurately assess the influence of the alternative radiopacifiers on cement crack propagation, fatigue crack growth rate tests were performed using disc-shaped compact tension specimens, with dimensions conforming to the ASTM E399 standard and as described by Ayre et al.<sup>6,55,56</sup> A modified microtome was used to cut a chevron notch, which ensured symmetrical crack growth. The initial crack length and specimen dimensions were measured using a travelling microscope (Pye Scientific, Cambridge, UK). In order to apply the load symmetrically across the sample, loose plates with oversize holes were used, which allowed the loading pins to rotate freely. The crack length was monitored using Krak-gauges and a constant current supply and amplifier designed and built by Evans.<sup>23</sup> Tests were performed in an Instron environmental chamber (Instron SFL, Bristol, UK) set at 37 °C and the current regulator and preamplifier were also kept in the environmental chamber to minimise drift. Two fatigue samples per group were tested until failure, using a 5 kN Dartec servohydraulic testing machine with an MTS FlexTest GT controller and MTS Multipurpose software (MTS, Eden Prairie, MN, USA).

Samples were cyclically loaded in load control with a sine wave at 5 Hz between 100 N and 10 N (R-ratio of 0.1), allowing for measurements of crack growth rates

through stress intensities of 0.3 to 0.9 MPa<sup>1/2</sup>. Prior to loading, samples were subject to a pre-cracking procedure to ensure an initial steady crack growth rate of 10<sup>-9</sup> m/cycle. For pre-cracking, a high cyclic load of 200 N at 5 Hz was applied and the load reduced by 10% after every 0.2 mm of crack growth. The crack length and number of cycles were measured during loading and the crack growth rate (da/dN in m/cycle) was calculated for every 0.2 mm of crack growth. The corresponding stress intensity factor range ( $\Delta K$ ) for each sample and crack length (ranging from 6–12 mm, in steps of 0.2 mm) was calculated based on the minimum and maximum load, sample dimensions and crack length as described by Ayre et al.<sup>6,55</sup> For each specimen, da/dN was plotted against  $\Delta K$  on logarithmic axes. The Paris Law ( $da/dN = A \Delta K^m$ ) was fitted to the results, yielding values for A (crack growth rate at  $\Delta K = 1$  MPa<sup>1/2</sup>) and m (change in crack growth rate over the range of  $\Delta K$  measured).

### Hydroxyapatite (HA) nucleation

HA nucleation was determined according to the ISO23317:2007 standard.<sup>57</sup> 2 mm thick by 10 mm square bone cement samples were prepared containing 10%w/w BaSO<sub>4</sub>, 10%w/w TiO<sub>2</sub>, 10%w/w ZrO<sub>2</sub>, 10% w/w silane-treated TiO<sub>2</sub> and 10%w/w silane-treated ZrO<sub>2</sub>. Two samples for each group and time point were used. Each sample was stored in 30 mL of simulated body fluid (SBF) based on a solution developed by Kokubo et al.<sup>58</sup> The samples and SBF were stored in a V-bottom container at 37 °C for 1 hour, 1 week and 4 weeks. After each time point, the samples were removed and washed twice with distilled deionised water to remove any unattached precipitates. The samples were then desiccated without heat to prevent crystallisation. The sample surface was examined by X-ray diffraction (XRD) using a Philips PW3830 X-ray generator with a PW1710 Diffractometer control (Philips Research, Eindhoven, The Netherlands) and X'pert Industry v1.1c software (PANalytical B.V., Almelo, The Netherlands). The samples were scanned between 3° and 50° (2 $\theta$ ) at a scan speed of 0.020°/s. After XRD, samples were imaged using scanning electron microscopy (SEM) for visual inspection of hydroxyapatite crystals as described below.

### Scanning electron microscopy

The fatigue fracture surfaces and hydroxyapatite test samples were gold coated using an k550x sputter coater (Emitech, Kent, UK) and imaged using an EBT1 scanning electron microscope (SEM Tech Ltd, Suffolk, UK) at 15 KeV.



### Cell attachment and viability

The MC3T3-E1 osteoblast precursor cell line (ATCC<sup>®</sup>, LGC Standards, Middlesex, UK) derived from mouse calvaria was used to investigate cell attachment and viability. Cells of passage 14–16 were maintained in  $\alpha$ -MEM supplemented with 10% foetal bovine serum and 1% penicillin/streptomycin at 37°C in 5% CO<sub>2</sub>. Four samples for each test group and time point were prepared (cylindrical 10 mm diameter by 2 mm height). The cylindrical samples were sterilized in 100% ethanol for 5 minutes and allowed to air dry under aseptic conditions. Samples were transferred to a 24 well-plate and approximately 6000 cells in 150  $\mu$ L of supplemented culture medium was seeded on top of each sample and incubated for 4 hours at 37°C in 5% CO<sub>2</sub> to allow attachment. After 4 hours, each well was flooded with 750  $\mu$ L of supplemented culture medium and incubated for 1, 4 and 24 hours. After each time point, the medium was removed and the samples washed with phosphate buffer saline (PBS) to remove non-adherent cells. Adherent cells were then fixed with 10%v/v neutral buffered formalin for 10 minutes before washing with PBS and staining with 1%w/v toluidine blue for 10 minutes. The stain was removed and the samples were washed twice with distilled water. The samples were left to dry and four random areas on the surface of each sample were imaged using an Olympus IX50 light microscope (Olympus, Southend-on-Sea, UK). The number of adherent cells were counted using ImageJ software (National Institutes of Health, Maryland, USA). The experiment was performed in triplicate.

For the cell viability assay, cement samples were prepared and sterilised as previously described. 3000 cells in 500  $\mu$ L of supplemented culture media were seeded on each sample surface and the samples incubated at 37°C in 5% CO<sub>2</sub> for 3 and 7 days, with the medium replaced every 2 days. At each time point, the samples were washed with PBS and moved to a new 24-well plate. 500  $\mu$ L of phenol-free  $\alpha$ -MEM and 100  $\mu$ L of CellTiter 96<sup>®</sup> AQueous One Solution Proliferation Assay (Promega Corporation, WI, USA) were added to each well and the plate was incubated in the dark for 2 hours. Wells containing cement samples without any cells were used as controls. After 2 hours, 100  $\mu$ L of the assay medium was moved to a 96-well plate and the absorbance was measured at 490 nm using a Packard Spectracount plate reader (Buckinghamshire, UK). The control sample absorbance was subtracted from the absorbance of samples with cells to account for background generated by the cement. The experiment was performed in triplicate.

### Statistical analysis

Statistical analyses were performed using GraphPad Prism version 8 for Mac (GraphPad Software, La Jolla California USA). Groups of data were tested for normality using a Shapiro-Wilk test. For data that approximately followed a normal distribution, a parametric analysis of variance (ANOVA) was performed with a Tukey-Kramer post hoc analysis (compressive strength, bending strength, cell attachment, cell viability and surface energy). For data that deviated from a normal distribution, a non-parametric Kruskal-Wallis test was performed with a Dunn's post hoc analysis (bending modulus and fracture toughness). The confidence interval for establishing significant differences between groups was set at 95% ( $p < 0.05$ ).

## Results

### Radiopacifier particle size

The volume median diameters ( $D_{50}$ ) for BaSO<sub>4</sub>, TiO<sub>2</sub> and ZrO<sub>2</sub> were 2.72  $\mu$ m, 0.53  $\mu$ m and 0.74  $\mu$ m respectively (Figure 2(a)). Both TiO<sub>2</sub> and ZrO<sub>2</sub> had unimodal distributions in the sub-micron region whilst BaSO<sub>4</sub> had a small volume percentage of sub-micron particles with most of the particles in the 1 to 10  $\mu$ m region.


### Radiopacity

Approximately 10 to 20%w/w TiO<sub>2</sub> or ZrO<sub>2</sub> were required to achieve similar radiopacity to the 10%w/w BaSO<sub>4</sub> samples and the commercial products (Figure 2(b)). Increasing the amount of TiO<sub>2</sub> and ZrO<sub>2</sub> in the cement samples resulted in a dose-dependent increase in radiopacity. At high concentrations (20 and 25%w/w), ZrO<sub>2</sub> gave slightly higher mean grey values compared to TiO<sub>2</sub>. PMMA without a radiopacifier had the lowest radiopacity when compared to all other samples.

### Fourier transform infrared spectroscopy of silane-treated TiO<sub>2</sub> and ZrO<sub>2</sub>

FT-IR spectra for silane-treated TiO<sub>2</sub> and ZrO<sub>2</sub> (Figure 2(c) and (d), respectively) confirmed that the particles were coated due to the presence of organic peaks similar to those of MPS. The most prominent peaks were the C=O stretch at 1730 cm<sup>-1</sup>, the C=C stretch at 1600 cm<sup>-1</sup>, the C-O-C and CH<sub>3</sub> peaks around 1300 cm<sup>-1</sup> and the two peaks at 1100 cm<sup>-1</sup> and 1200 cm<sup>-1</sup> associated with silicon. Both radiopacifiers showed characteristics of their original untreated material in the form of a small broad peak at around





**Figure 2.** (a) TiO<sub>2</sub> and ZrO<sub>2</sub> radiopacifiers had sub-micron particle sizes, whilst BaSO<sub>4</sub> particles were larger with a smaller volume percentage in the sub-micron region. (b) Analysis of X-ray images showed that greater than 10%w/w TiO<sub>2</sub> or ZrO<sub>2</sub> resulted in similar radiopacity to the 10%w/w BaSO<sub>4</sub> cements. Fourier transform infrared spectroscopy confirmed the silane coating on (c) TiO<sub>2</sub> and (d) ZrO<sub>2</sub> radiopacifiers by the presence of organic and silicon peaks.

1600 cm<sup>-1</sup> and a reduction in intensity for wavelength values below 900 cm<sup>-1</sup>.

### Setting time and temperature

Cement samples containing ZrO<sub>2</sub> had short setting times (Table 2, 10%w/w ZrO<sub>2</sub>, 10%w/w silane ZrO<sub>2</sub> and Palacos R). 10%w/w silane ZrO<sub>2</sub> and Cemex samples had the lowest maximum temperature, whilst 10% w/w TiO<sub>2</sub> and 10%w/w ZrO<sub>2</sub> had the highest maximum temperature. Silane treatment of both the TiO<sub>2</sub> and ZrO<sub>2</sub> slightly reduced the maximum temperature.

### Surface energy

Cements without a radiopacifier and cements with 10%w/w BaSO<sub>4</sub> had a significantly lower surface energy compared to cements with TiO<sub>2</sub> as their radiopacifier (Table 2,  $p < 0.01$ , untreated and silane-treated). The addition of both untreated and silane-treated TiO<sub>2</sub> resulted in a more hydrophilic cement. There were no significant differences between the surface energies of TiO<sub>2</sub> and ZrO<sub>2</sub> containing samples ( $p > 0.05$  for both untreated and silane-treated

samples). Silane treating TiO<sub>2</sub> and ZrO<sub>2</sub> did not significantly alter the surface energy of the samples when compared to untreated TiO<sub>2</sub> and ZrO<sub>2</sub> ( $p > 0.05$ ). Interestingly however, silane-treated ZrO<sub>2</sub> samples had a significantly higher surface energy when compared to cements with no radiopacifier ( $p = 0.01$ ) and cements with 10%w/w BaSO<sub>4</sub> ( $p = 0.002$ ) as the radiopacifier.


### Compressive and bending properties

Figure 3(a) shows the compressive strength of cement formulations with different radiopacifiers. PMMA without a radiopacifier had a significantly lower compressive strength when compared to PMMA with 10% w/w BaSO<sub>4</sub> ( $p < 0.001$ ). Overall, no trends were observed in compressive strength with the addition of up to 25%w/w TiO<sub>2</sub> or ZrO<sub>2</sub> to the cements. Cements containing 5, 15, 20 and 25%w/w untreated TiO<sub>2</sub> ( $p < 0.001$ ) and 5, 15, 20 and 25%w/w ZrO<sub>2</sub> ( $p < 0.05$ ) had significantly lower compressive strengths compared to 10%w/w BaSO<sub>4</sub> cement. Silane treatment of TiO<sub>2</sub> and ZrO<sub>2</sub> significantly increased the

**Table 2.** Setting properties and average surface energy of commercial bone cements and cements containing various radiopacifiers.

Sample	Setting time (s)	Setting temperature (°C)	Maximum temperature (°C)	Surface energy (mN/m)
Cemex	738	46.5	69.8	
Palacos R	479	52.1	78.5	
0%w/w radiopacifier	615	51.4	81.6	30.6 ± 3.8
10%w/w BaSO <sub>4</sub>	665	49.2	76.2	28.8 ± 3.0
10%w/w TiO <sub>2</sub>	631	52.9	82.1	44.5 ± 3.5 <sup>+++/**</sup>
10%w/w silane TiO <sub>2</sub>	579	51.0	79.6	41.7 ± 4.2 <sup>+++/**</sup>
10%w/w ZrO <sub>2</sub>	441	53.3	82.2	36.7 ± 3.8
10%w/w silane ZrO <sub>2</sub>	442	46.1	69.1	41.6 ± 6.2 <sup>+++/*</sup>

<sup>+++</sup>p < 0.001 compared to 10%w/w BaSO<sub>4</sub>; \* p < 0.05, \*\*p < 0.01, \*\*\*p < 0.001 compared to 0%w/w radiopacifier.



**Figure 3.** (a) Compressive strength, (b) bending strength, (c) bending modulus and (d) fracture toughness of commercial cements, cement samples containing 10%w/w BaSO<sub>4</sub>, 0 to 25%w/w TiO<sub>2</sub> or ZrO<sub>2</sub> and 10%w/w silane-treated TiO<sub>2</sub> or ZrO<sub>2</sub>. Addition of radiopacifiers increased the bending modulus and decreased the bending strength and fracture toughness of samples in a dose-dependent manner. Silane-treating TiO<sub>2</sub> improved the compressive strength, bending modulus and bending strength of the samples compared to untreated TiO<sub>2</sub> samples. (\*p < 0.05, \*\* p < 0.05, \*\*\* p < 0.001; + p < 0.05, ++ p < 0.01, +++ p < 0.001 compared to 10% BaSO<sub>4</sub>; † p < 0.05, †† p < 0.01, ††† p < 0.001 compared to 10%w/w radiopacifier).

compressive strength compared to the cement samples with the same amount of untreated radiopacifier (10%w/w  $\text{TiO}_2$  and 10%w/w  $\text{ZrO}_2$ ,  $p < 0.05$ ). Silane-treated 10%w/w  $\text{TiO}_2$  had a significantly higher compressive strength compared to 10%w/w  $\text{BaSO}_4$  and cement without a radiopacifier ( $p < 0.001$ ). Cements with silane-treated 10%w/w  $\text{ZrO}_2$  had a significantly higher compressive strength compared to cements with no radiopacifier ( $p < 0.001$ ). All compressive strength values were similar to the two commercially available products (Cemex Isoplastic and Palacos R).

Addition of greater than or equal to 5%w/w  $\text{TiO}_2$  ( $p < 0.01$ ) or 10%w/w  $\text{ZrO}_2$  ( $p < 0.001$ ) to PMMA significantly decreased its bending strength (compared to 0%w/w radiopacifier, Figure 3(b)). Similarly, cement samples containing silane-treated  $\text{TiO}_2$  or silane-treated  $\text{ZrO}_2$  had a significantly lower bending strength compared to PMMA with no radiopacifier ( $p < 0.05$ ). Increasing the amount of  $\text{TiO}_2$  in the samples caused a dose-dependent reduction in bending strength, with 15%w/w  $\text{TiO}_2$  or more having a significantly lower bending strength compared to 10%w/w  $\text{BaSO}_4$  ( $p < 0.01$ ). This was not the case for  $\text{ZrO}_2$  samples, which although appeared to have a reduction in bending strength was not significantly different to 10%w/w  $\text{BaSO}_4$  ( $p > 0.05$ ). There was no significant difference in bending strength between  $\text{TiO}_2$  and  $\text{ZrO}_2$  containing cements ( $p > 0.05$ ) and no significant differences between 10%w/w untreated and silane-treated  $\text{TiO}_2$  or  $\text{ZrO}_2$ . Palacos R had a significantly higher bending strength when compared to all cement samples ( $p < 0.01$ ), except 0%w/w radiopacifier samples. Cemex Isoplastic was not significantly different to any formulation ( $p > 0.05$ ), with the exception of 0%w/w radiopacifier samples, which had significantly higher bending strength ( $p < 0.001$ ).

A trend was observed whereby increasing the amount of  $\text{TiO}_2$  and  $\text{ZrO}_2$  resulted in an increase in the bending modulus of the cements (Figure 3(c)). The bending moduli for 25%w/w  $\text{TiO}_2$  samples and silane-treated  $\text{TiO}_2$  samples were significantly higher than that of samples without a radiopacifier ( $p = 0.009$  and  $p = 0.0008$  respectively). No significant differences were observed between all formulations and 10%w/w  $\text{BaSO}_4$  samples. Although  $\text{TiO}_2$  containing samples appeared to have a higher modulus than  $\text{ZrO}_2$  containing samples at higher concentrations, this was not statistically significant, even for the silane-treated samples, where a large difference was observed ( $p > 0.05$ ). All cement formulations had similar bending moduli to the commercial products, with the exception of silane  $\text{TiO}_2$ , which had a significantly higher modulus than Cemex Isoplastic ( $p = 0.01$ ).

Average compressive strength, bending strength and bending modulus values for the tested cement


formulations are shown in the supplementary materials (Table S1) along with their respective standard deviations.

### Fracture toughness

Similar to the bending strength, addition of radiopacifiers to PMMA appeared to adversely affect the fracture toughness of PMMA in a dose-dependent manner (Figure 3(d)). Samples with 25%w/w  $\text{TiO}_2$  had significantly lower fracture toughness values than PMMA samples without any radiopacifier ( $p = 0.04$ ). There were no significant differences in fracture toughness between samples containing 10%w/w  $\text{BaSO}_4$  and all other formulations ( $p > 0.05$ ); and silane treatment of  $\text{TiO}_2$  and  $\text{ZrO}_2$  did not significantly improve the fracture toughness of the samples. There were no significant differences between samples containing  $\text{TiO}_2$  and  $\text{ZrO}_2$  (for both untreated and silane-treated samples,  $p > 0.05$ ). Fracture toughness values for all formulations were found to fall within the range of those obtained for the two commercial products (Cemex Isoplastic and Palacos R). Interestingly, Cemex Isoplastic was found to have a significantly lower fracture toughness when compared to PMMA without a radiopacifier ( $p = 0.005$ ) and when compared to Palacos R cement ( $p = 0.0002$ ). Cement samples with 20 and 25%w/w  $\text{TiO}_2$  and 25%w/w  $\text{ZrO}_2$  had significantly lower fracture toughness values than Palacos R cement ( $p < 0.05$ ). Average fracture toughness values along with their respective standard deviations for the cements tested are shown in the supplementary materials (Table S1).

### Fatigue crack growth rate

10%w/w  $\text{ZrO}_2$  had the highest crack growth rates over the stress intensities tested (Figure 4(a)). 10%w/w  $\text{TiO}_2$  had similar crack growth rates compared to 10%w/w  $\text{BaSO}_4$  samples and radiopacifier-free samples. The commercial cements had the lowest crack growth rates. This is also shown in Table 3 where A (crack growth rate at  $\Delta K = 1 \text{ MPam}^{1/2}$ ) and m (change in crack growth rate over the range of  $\Delta K$  measured) were both lower for the commercial cements. Silane treating  $\text{TiO}_2$  and  $\text{ZrO}_2$  resulted in a slight downward shift of the fatigue crack propagation plots, indicating improved crack growth resistance (Figure 4(b)). Fitting the Paris Law to the data showed a reduction in the crack growth rates at  $\Delta K = 1 \text{ MPam}^{1/2}$  (A coefficient), however no substantial change in crack growth rates over the range of  $\Delta K$  tested (m coefficient, Table 3). At low stress intensities, silane-treated cements had lower crack growth rates, whilst at high stress intensities,



**Figure 4.** (a) Fatigue crack propagation results for commercial bone cement samples and samples containing no radiopacifier, 10%w/w BaSO<sub>4</sub>, 10%w/w TiO<sub>2</sub> or 10%w/w ZrO<sub>2</sub> as the radiopacifier. The addition of ZrO<sub>2</sub> resulted in higher crack growth rates compared to other formulations. (b) Silane-treated TiO<sub>2</sub> or ZrO<sub>2</sub> reduced crack growth rates. Large radiopacifier agglomerates were observed on the fracture surfaces of (c) BaSO<sub>4</sub>, (d) TiO<sub>2</sub> or (e) ZrO<sub>2</sub> samples with voids surrounding the agglomerates. Silane treatment of (f) TiO<sub>2</sub> and (g) ZrO<sub>2</sub> reduced the size and number of agglomerates observed. Red arrows indicate PMMA beads, green arrows indicate radiopacifier agglomerations, yellow arrows indicate pores/voids and white arrows indicate microcracks.

comparable crack growth rates to the 10%w/w BaSO<sub>4</sub> cement and the commercial cements were observed.

Large radiopacifier agglomerations in the fracture surfaces were observed for the 10%w/w BaSO<sub>4</sub>, 10%w/w TiO<sub>2</sub> and 10%w/w ZrO<sub>2</sub> samples when viewed under SEM (Figure 4(c) to (e) respectively), with agglomerates ranging from 20 to 200 μm in length (up to one hundred fold the size of the individual radiopacifier particles). Large voids were also observed surrounding the agglomerations. Silane treatment improved the dispersion of TiO<sub>2</sub> particles (Figure 4 (f)), however for silane-treated 10%w/w ZrO<sub>2</sub> large agglomerations were still present (Figure 4(g)). Both silane fracture surfaces however, appeared visibly rougher than the untreated TiO<sub>2</sub> and ZrO<sub>2</sub> fracture surfaces indicating a less brittle fracture (Figure 4(f) and (g)). Semi-circular microcracks were observed on the fracture surfaces of the silane-treated 10%w/w TiO<sub>2</sub> samples, indicative of microcracks forming ahead of the crack tip (Figure 4(f)). Microcracks induce plastic deformation ahead of the crack tip and cause the main crack to deviate or branch out, slowing crack propagation and reducing the stress intensity at the tip of the crack.

### Hydroxyapatite nucleation

XRD detected the radiopacifiers on the surface of the cement samples, as shown by peaks at the same positions as the reference materials (radiopacifier powders,

bottom spectra of Figure 5(a), (d), (g), (j), and (m)). XRD confirmed that the anatase phase of TiO<sub>2</sub> and the tetragonal phase of ZrO<sub>2</sub> were present (Figure 5(d) and (g) respectively). No HA was detected on the surface of cements containing BaSO<sub>4</sub>, ZrO<sub>2</sub> or silane-treated ZrO<sub>2</sub> for all time points (Figure 5(a), (j), and (m), respectively). This was confirmed with SEM images at 1 and 4 weeks, where no changes in surface topography or deposition of HA were observed (Figure 5(b), (c), (k), (l), (n), and (o)). For the BaSO<sub>4</sub> samples, after 1 week in SBF an additional peak at 38.3° was observed (Figure 5(a)) however this peak did not align with those of HA and was not present at 4 weeks.

Cement samples containing TiO<sub>2</sub> had peaks at approximately 11.0°, 22.0°, 22.8° and 32.3° after 4 weeks in SBF, which aligned with HA peaks (Figure 5(d)). Small crystal structures were observed on the surfaces of these samples under SEM after 1 week and 4 weeks incubation (Figure 5(e) and (f) respectively). Peaks at 44.5° after 1 week and 20.5° after 4 weeks were also detected, however these did not align with HA peaks.

Silane-treated TiO<sub>2</sub> samples also had peaks at the same positions as HA after 4 weeks in SBF. These peaks were at approximately 11.0°, 16.9°, 22.8° and 32.3° (Figure 5(g)). Although several HA peaks were detected by XRD and observed using SEM, complete surface coverage with HA after 4 weeks was not observed.



### Cell attachment and viability

Figure 6(a) shows the number of cells attached to the surface of the cement samples after 1, 4 and 24 hours incubation. After 1 hour incubation, samples containing silane-treated  $\text{TiO}_2$  had significantly higher numbers of attached MC3T3-E1 cells when compared to


**Table 3.** Best-fit values of the Paris Law constants (A and m).

Sample	A	m	Correlation coefficient
Palacos R	$3.73 \times 10^{-07}$	4.65	0.61
Cemex	$5.39 \times 10^{-07}$	5.92	0.82
0% radiopacifier	$3.53 \times 10^{-06}$	5.49	0.69
10% $\text{BaSO}_4$	$4.83 \times 10^{-07}$	3.73	0.67
10% $\text{TiO}_2$	$3.00 \times 10^{-06}$	6.03	0.57
10% silane $\text{TiO}_2$	$6.80 \times 10^{-07}$	5.94	0.92
10% $\text{ZrO}_2$	$6.92 \times 10^{-05}$	6.88	0.73
10% silane $\text{ZrO}_2$	$5.51 \times 10^{-06}$	6.76	0.84


A represents the crack growth rate (at  $\Delta K = 1 \text{ MPam}^{1/2}$ ) and m the change in crack growth rate over the range of  $\Delta K$  measured.

the 10%w/w  $\text{BaSO}_4$  ( $p=0.001$ ), 0%w/w radiopacifier ( $p=0.002$ ), 10%w/w  $\text{TiO}_2$  ( $p=0.04$ ), 10%w/w  $\text{ZrO}_2$  ( $p=0.0004$ ) and silane-treated  $\text{ZrO}_2$  ( $p=0.004$ ) cements. There were no other significant differences at 1 hour. At 4 and 24 hours, silane-treated  $\text{TiO}_2$  had significantly higher numbers of attached MC3T3-E1 cells when compared to 0%w/w radiopacifier cements ( $p=0.03$  for 4 hours and  $p=0.004$  for 24 hours). Interestingly at 24 hours, 10%w/w  $\text{TiO}_2$  cements also had significantly higher number of attached cells when compared to 0%w/w radiopacifier cements ( $p=0.03$ ).

Although MC3T3-E1 cells attached more readily on the surface of silane-treated  $\text{TiO}_2$  samples, the results from the cell viability assay showed that the samples with silane-treated  $\text{TiO}_2$  and  $\text{ZrO}_2$  had slightly lower 490 nm absorbance values, indicating a lower number of viable cells (Figure 6(b)). This reduction was only statistically significant for silane-treated  $\text{ZrO}_2$  samples, which at 3 days had significantly lower cell viability when compared to 10%w/w  $\text{BaSO}_4$  ( $p=0.03$ ) and 0%w/w radiopacifier ( $p=0.04$ ) samples. At 7 days this was also the case, with silane-treated  $\text{ZrO}_2$  samples



**Figure 5.** X-ray diffraction (XRD) spectra and scanning electron microscopy (SEM) images of (a to c)  $\text{BaSO}_4$ , (d to f)  $\text{TiO}_2$ , (g to i) silane-treated  $\text{TiO}_2$ , (j to l)  $\text{ZrO}_2$  and (m to o) silane-treated  $\text{ZrO}_2$  samples following (b, e, h, k, n) 1 and (c, f, i, l, o) 4 weeks incubation in simulated body fluid. The nucleation of rod-like hydroxyapatite crystals was observed on cement samples containing  $\text{TiO}_2$  (untreated (e and f) and silane-treated (h to j)) as highlighted by alignment of XRD peaks with hydroxyapatite (d and g) and white arrows in the SEM images (e, f, h and i).



**Figure 6.** (a) Cell attachment to cement samples containing different radiopacifiers after incubation for 1, 4 and 24 hours; and (b) cell viability following incubation for 3 and 7 days. Samples containing silane-treated TiO<sub>2</sub> had a significantly higher number of attached cells after 1 hour incubation compared to samples containing 10%w/w BaSO<sub>4</sub>. Silane-treated ZrO<sub>2</sub> samples had a significantly reduced cell viability at 3 and 7 days compared to samples containing 10%w/w BaSO<sub>4</sub>. (\*  $p < 0.05$ , \*\*  $p < 0.01$ , \*\*\*  $p < 0.001$ ; +  $p < 0.05$ , ++  $p < 0.01$ , +++  $p < 0.001$  compared to 10%w/w BaSO<sub>4</sub>; †  $p < 0.05$  compared to 10%w/w radiopacifier).

having a significantly lower cell viability when compared to 10% BaSO<sub>4</sub> ( $p = 0.0009$ ), 0%w/w radiopacifier ( $p = 0.004$ ), 10%w/w TiO<sub>2</sub> ( $p = 0.003$ ), 10%w/w ZrO<sub>2</sub> ( $p = 0.01$ ) and silane-treated TiO<sub>2</sub> ( $p = 0.03$ ) samples. Interestingly between days 3 and 7 there was still an increase in absorbance values for the silane-treated TiO<sub>2</sub> and silane-treated ZrO<sub>2</sub> samples, indicating the cells were still proliferating, however at a potentially lower rate than on other cement surfaces.

Table S2 (supplementary materials) shows the average cell attachment and cell viability values and standard deviations for the tested cements.

## Discussion

The addition of radiodense inorganic particles to PMMA allows the cement to be observed using X-ray imaging, however previous studies have shown that this approach can adversely influence the mechanical and fatigue crack propagation of the material as well as induce an osteolytic biological response, potentially contributing to cement failure. Substantial research has been undertaken to develop novel radiopacifiers, particularly based on nano-particles;<sup>38,39</sup> however concerns regarding environmental and systemic toxicity have limited their clinical translation.<sup>41</sup> This study has therefore investigated whether alternative radiopacifiers (anatase TiO<sub>2</sub> or yttria-stabilised ZrO<sub>2</sub>) offer any physicochemical or biological advantages over conventional BaSO<sub>4</sub> radiopacifiers and whether silane treatment can further enhance cement properties. To investigate this, a model cement was formulated and

the conventional radiopacifier (BaSO<sub>4</sub>) substituted to investigate the impact of the alternative radiopacifier alone. Commercial products were included in this study as reference materials for the ISO/ASTM standard mechanical, fracture toughness and fatigue crack propagation tests.

While the laser diffraction results show that the TiO<sub>2</sub> and ZrO<sub>2</sub> powders used in this study were sub-micron, the particle diameters measured were not considered to be within the nano-scale according to ISO definitions (between 1 nm to 100 nm).<sup>59</sup> For this reason, and due to the agglomerations observed, the differences in results between the different radiopacifiers are likely not attributed to size differences, but rather to the properties of the materials.

The ability of a material to attenuate and absorb X-rays is governed by the energy levels used by the imaging equipment and the atomic number and density of the material, which in turn affects what is known as its mass attenuation coefficient.<sup>60</sup> Beyond energy levels of around 15 keV, PMMA does not attenuate X-rays effectively (as shown in Figure 1(b) and Fig. S1), highlighting the need for radiopacifiers. Addition of 10%w/w or more TiO<sub>2</sub> or ZrO<sub>2</sub> to PMMA gave similar radiopacity to 10%w/w BaSO<sub>4</sub> and commercial cements. At higher concentrations (20 and 25%w/w), ZrO<sub>2</sub> had slightly higher mean grey values when compared to TiO<sub>2</sub>. This aligns with the theoretical transmitted intensity for ZrO<sub>2</sub> at 35 keV, which is substantially lower than that of TiO<sub>2</sub> and BaSO<sub>4</sub> (Table S3). Clinically however, X-ray irradiation is performed at higher energy levels ( $\approx 70$  keV) to minimise radiation doses. At this level, the transmitted intensity

for titanium is greater (Table S3) and may result in reduced radiopacity. Future work would therefore be required to establish the clinical performance of the alternative radiopacifiers, taking into account this higher energy levels.

FT-IR results confirmed that the silane was bound to the surface of the radiopacifiers, similar to other studies using the same silane (MPS) and similar protocols to effectively coat titanium dental implants and yttria-stabilised zirconium ceramics.<sup>61,62</sup>

The higher thermal conductivity of TiO<sub>2</sub> did not drastically alter the setting properties and heat dissipation of bone cement. Higher levels of metal oxide fillers ( $\approx 40\%$  w/w) may be required to observe such an effect as reported in the literature.<sup>63–66</sup> Chou and Mariatti<sup>67</sup> found the peak setting temperature of bone cement to reduce with increased nano-TiO<sub>2</sub> loading. Interestingly the setting time was reduced when using 10% w/w yttria-stabilised ZrO<sub>2</sub> as also observed with Palacos R, which uses a non-stabilised ZrO<sub>2</sub> radiopacifier. It is speculated that the surface properties of ZrO<sub>2</sub> may influence the orientation of polymer chains, which may influence the free radical polymerisation reaction.<sup>68</sup>

PMMA is hydrophobic in nature, as reflected by its low surface energy, and the addition of hydrophilic radiopacifiers resulted in an overall increase in surface energy. Reported surface energy values for commercial bone cements (CMW1  $\approx 29.4$  mN/m),<sup>69</sup> native PMMA ( $\approx 39$  mN/m),<sup>70</sup> BaSO<sub>4</sub> ( $\approx 33$  mN/m)<sup>71</sup> and ZrO<sub>2</sub> ( $\approx 42$  mN/m)<sup>72</sup> were consistent with those obtained experimentally for the modified PMMA samples (Table 2). Addition of 10% w/w TiO<sub>2</sub> to PMMA significantly increased the surface energy of the material, likely due to the high surface energy of native anatase TiO<sub>2</sub> ( $\approx 91$  mN/m).<sup>46</sup> The presence of a silane did not further significantly alter the surface energy of the cements, likely due to the negligible amounts of silane present in relation to the bulk of the cement.

No clear trend in compressive strength was observed when increasing TiO<sub>2</sub> or ZrO<sub>2</sub> concentrations up to 25% w/w. Fukuda et al.<sup>73,74</sup> also showed no dose-dependent effect on compressive strength with the addition of up to 20% w/w rutile TiO<sub>2</sub> to bone cement. Under the high compressive cross-head speeds used, the weaker PMMA beads or the interface between PMMA and the radiopacifier are likely to fail before the stiffer TiO<sub>2</sub> or ZrO<sub>2</sub> particles. Silane treatment of the TiO<sub>2</sub> and ZrO<sub>2</sub> however significantly increased the compressive strength. Goto et al.<sup>75</sup> observed similar results whereby silane-treating nano-TiO<sub>2</sub> (50% w/w) resulted in increased compressive strength. Coating the high surface energy (hydrophilic) radiopacifier with a low surface energy (hydrophobic) silane coupling agent, would improve the compatibility with PMMA and prevent agglomerates.<sup>46</sup> Li et al.<sup>76</sup>

found coating TiO<sub>2</sub> with a surfactant known as Span 60 increased the overall hydrophobicity of TiO<sub>2</sub> and prevented it from agglomerating.

The proportional increase in bending modulus with increased radiopacifier content can be linked to stiffer particles replacing the softer PMMA particles. After silane treating the TiO<sub>2</sub>, a significant increase in bending modulus was observed, indicating enhanced integration with the PMMA matrix. The effect however was not observed for silane-treated ZrO<sub>2</sub> samples. For TiO<sub>2</sub> samples, the increased modulus resulted in a dose-dependent decrease in bending strength. Chou and Mariatti<sup>67</sup> showed similar results where addition of nano-TiO<sub>2</sub> to bone cement decreased the strain at break and flexural strength, again linked to increased agglomerates and void content. Fukuda et al.<sup>73,74</sup> also found the same trend where bending modulus increased between 5 and 20% w/w rutile TiO<sub>2</sub>, causing a dose-dependent decrease in bending strength. The bending modulus and strength of bone cement containing ZrO<sub>2</sub> however appeared to be less concentration dependent. Silane treatment of TiO<sub>2</sub> reversed the detrimental effect on the bending strength; which is attributed to enhanced dispersion and adhesion to the PMMA matrix. Poor adhesion of the radiopacifier would result in detachment from the PMMA matrix under strain, creating voids and weakening the cement. This hypothesis is further reinforced by the fact that plain PMMA (with no radiopacifier) had the highest bending strength values, highlighting the role radiopacifiers play in initiating cement failure. The fracture toughness results reflected those of the bending strength, with a dose dependent decrease with increasing TiO<sub>2</sub> concentrations. Similar to the bending strength, the fracture toughness of ZrO<sub>2</sub> samples were less affected by the amount of radiopacifier incorporated into the cement. Interestingly however silane treatment of TiO<sub>2</sub> and ZrO<sub>2</sub> did not significantly enhance the fracture toughness of the samples. This may be due to the high crack propagation rates associated with this type of test. Further fatigue testing was performed to establish differences under low crack propagation rates.

The fatigue crack propagation tests showed that the radiopacifier-free samples did not have the lowest crack growth rates. This supports the argument put forward by several authors that radiopacifiers can also reduce crack propagation rates.<sup>24–31</sup> Compared to the 10% w/w BaSO<sub>4</sub> and the commercial cements, the addition of 10% w/w TiO<sub>2</sub> or ZrO<sub>2</sub> increased fatigue crack growth rates. Closer examination of the fracture surfaces identified large agglomerates for all the radiopacifiers tested with visible voids surrounding them. These features may act as stress concentrations under load and sites for crack initiation.<sup>15–20,32,77</sup> Yttria-stabilised ZrO<sub>2</sub> was expected to reduce fatigue



crack propagation in the cement due to its transformation toughening mechanism, however in this study it increased crack growth rates. When silane treating  $\text{TiO}_2$  and  $\text{ZrO}_2$ , an improvement in the crack growth rates were observed. SEM images of the fracture surfaces of the silane-treated  $\text{TiO}_2$  and  $\text{ZrO}_2$  samples showed fewer agglomerations and rougher fracture surfaces. Better dispersion would create fewer stress concentrations (known to initiate cracks) and enhanced adhesion would require higher stresses to de-bond the particle from the polymer matrix. As rigid particles do not deform easily, enhanced adhesion might also induce higher levels of plastic deformation in the surrounding polymer matrix, resulting in a tougher material. When functionalising nano- $\text{ZrO}_2$  and nano- $\text{BaSO}_4$  with a silane coupling agent, Gillani et al.<sup>78</sup> found that cements with unfunctionalised radiopacifiers caused brittle failure whilst functionalised radiopacifiers caused plastic failure modes.

After incubation for 4 weeks in simulated body fluid, only the  $\text{TiO}_2$ -containing samples showed evidence of HA nucleation. Studies have shown the negatively charged hydroxide and Lewis Base surface tension parameter of anatase  $\text{TiO}_2$  (used in this study) is more effective at inducing HA nucleation.<sup>44,79</sup> The similarity between the surface energy of  $\text{TiO}_2$  ( $\approx 91 \text{ mN/m}$ )<sup>46</sup> and that of HA ( $\approx 72\text{--}95 \text{ mN/m}$ )<sup>80</sup> and the close lattice match with HA may also be a contributing factor.

MC3T3-E1, a murine calvarial osteoblast precursor cell line, was selected for this study as it is a well-documented model for studying attachment, proliferation and mineralisation on the surface of materials.<sup>81</sup> The use of  $\text{TiO}_2$  and in particular, silane-treated  $\text{TiO}_2$ , was found to enhance MC3T3-E1 cell attachment. This increased cell attachment may be attributed to the increased hydrophilicity of the  $\text{TiO}_2$  cements as previously discussed or due to the calcium ion interaction that occurs with  $\text{TiO}_2$ , which selectively adsorbs serum proteins.<sup>43</sup> Research by Wei et al.<sup>82</sup> using a thin film of hexamethyldisiloxane (HMDSO) with and without oxygen plasma treatment showed hydrophilic surfaces preferentially bound fibronectin, which in turn correlated with increased MC3T3-E1 attachment, whilst hydrophobic surfaces preferentially bound albumin resulting in lower cell attachment. Fibronectin and vitronectin are often reported to play a vital role in osteoblast attachment and the improved rate of attachment between the bone cement samples may be linked to these serum proteins. A more rapid rate of osteoblast-like cell attachment as observed in this study has the potential to enhance the rate of osseointegration of bone cement. Fukuda et al.<sup>73</sup> demonstrated this in an *in vivo* rabbit femoral model where addition of rutile  $\text{TiO}_2$  to bone cement was found to

enhance osteoconductivity. Due to the higher acidity, lower surface zeta potential and closer lattice match of anatase with HA when compared to rutile,<sup>44</sup> there is potential to achieve further osteogenic benefits when using anatase form of  $\text{TiO}_2$  as a radiopacifier.

Although silane-treated  $\text{TiO}_2$  samples had increased MC3T3-E1 cell attachment, longer-term incubation (3 and 7 days) showed slightly lower cell viability on the silane-treated  $\text{TiO}_2$  surfaces and significantly lower cell viability on the  $\text{ZrO}_2$  surfaces. A study investigating the toxicity of a range of silanes (including MPS) used to treat HA particles found that extracts from HA-treated particles only caused mild cytotoxicity.<sup>83</sup> Other studies investigating the toxicity of silane-treated radiopacifiers in bone cement did not observe any *in vitro* or *in vivo* toxicity.<sup>75,78,84</sup> It is probable that the silane itself is not overtly toxic, but may influence cell numbers through other mechanisms such as reduced cell metabolism or proliferation. This is supported by data between days 3 and 7 showing an increase in cell viability for the silane-treated  $\text{TiO}_2$  and silane-treated  $\text{ZrO}_2$  samples, however at lower proliferation rates than on other cement surfaces. Future research should explore the effect of the silane (MPS) on the expression of cell proliferation markers, such as Ki67, proliferating cell nuclear antigen (PCNA) and minichromosome maintenance 2 (MCM-2).

## Conclusion

This study has investigated the potential for using anatase  $\text{TiO}_2$  and yttria-stabilised  $\text{ZrO}_2$  as alternative radiopacifiers for PMMA bone cement. Addition of greater than 10%w/w  $\text{TiO}_2$  and  $\text{ZrO}_2$  resulted in a similar radiopacity to 10%w/w  $\text{BaSO}_4$  and commercial products when tested at 35 keV. The addition of anatase  $\text{TiO}_2$  and yttria-stabilised  $\text{ZrO}_2$  to bone cement however resulted in a reduction in bending strength and fracture toughness, which was dose dependent for  $\text{TiO}_2$ ; this reduction was reversed with silane treatment to the levels of the cements containing 10%w/w  $\text{BaSO}_4$  and the commercial products. These radiopacifiers were also found to increase the fatigue crack growth rates of the cement due to the formation of agglomerations and voids; this was again largely reversed by silane treatment of  $\text{TiO}_2$  with better management of crack propagation. Silane treating  $\text{TiO}_2$  in particular, enhanced radiopacifier dispersion and adhesion to the PMMA matrix. Furthermore, silane-treated  $\text{TiO}_2$  as a radiopacifier enhanced nucleation of HA and increased MC3T3-E1 cell attachment to the cement *in vitro*, with limited effect on cell viability. This work demonstrates some potential benefits associated with silane-treated anatase  $\text{TiO}_2$  as a radiopacifier for bone cement over conventional radiopacifiers.



## Acknowledgements

The authors would like to acknowledge Dr Mari Novell and the Central Biotechnology Services (CBS) at Cardiff University for their support with the X-ray imaging.

## Declaration of conflicting interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

## Funding

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by the Biomechanics and Bioengineering Research Centre Versus Arthritis at Cardiff University (grant number: 20781) and the Cardiff Institute of Tissue Engineering and Repair.

## ORCID iD

Wayne Nishio Ayre  <https://orcid.org/0000-0003-2405-1876>

## Supplemental material

Supplementary material for this article is available online.

## References

1. John C. Anchorage of the femoral head prosthesis to the shaft of the femur. *J Bone Joint Surg Br Vol* 1960; 42-B: 28–30.
2. National Joint Registry UK. National Joint Registry for England and Wales, 16th Annual Report 2019, <https://reports.njrcentre.org.uk/Portals/0/PDFdownloads/NJR%2016th%20Annual%20Report%202019.pdf> (2019, accessed 26 April 2020).
3. Balen R, da Costa WV, de Lara Andrade J, et al. Structural, thermal, optical properties and cytotoxicity of PMMA/ZnO fibers and films: potential application in tissue engineering. *Appl Surf Sci* 2016; 385: 257–267.
4. Zahari NK, Idrus RBH and Chowdhury SR. Laminin-coated poly(methyl methacrylate) (PMMA) nanofiber scaffold facilitates the enrichment of skeletal muscle myoblast population. *Int J Mol Sci* 2017; 18: 2242.
5. Matbouei A, Fathi A, Rabiee SM, et al. Layered manufacturing of a three-dimensional polymethyl methacrylate (PMMA) scaffold used for bone regeneration. *Mater Technol* 2019; 34: 167–177.
6. Ayre WN, Birchall JC, Evans SL, et al. A novel liposomal drug delivery system for PMMA bone cements. *J Biomed Mater Res B Appl Biomater* 2016; 104: 1510–1524.
7. Alves Batista F, Brena Cunha Fontele S, Beserra Santos LK, et al. Synthesis, characterization of  $\alpha$ -terpineol-loaded PMMA nanoparticles as proposed of therapy for melanoma. *Mater Today Commun* 2020; 22: 100762.
8. Bettencourt A and Almeida AJ. Poly(methyl methacrylate) particulate carriers in drug delivery. *J Microencapsul* 2012; 29: 353–367.
9. Arcos D, Ragel CV and Vallet-Regí M. Bioactivity in glass/PMMA composites used as drug delivery system. *Biomaterials* 2001; 22: 701–708.
10. Lewis G. Fatigue testing and performance of acrylic bone-cement materials: state-of-the-art review. *J Biomed Mater Res B Appl Biomater* 2003; 66B: 457–486.
11. Hamadouche M, Baqué F, Lefevre N, et al. What is the optimal surface finish of a cemented femoral component? *Orthopaed Proc* 2010; 92B: 300–300.
12. Higa M, Manabe T, Nakamura Y, et al. Effect of hip stem cross-sectional geometry on cement stresses. *Orthopaed Proc* 2017; 99-B: 14–14.
13. Crowninshield RD, Brand RA, Johnston RC, et al. The effect of femoral stem cross-sectional geometry on cement stresses in total hip reconstruction. *Clin Orthopaed Relat Res* 1980; 146: 71–77.
14. Sinnott-Jones PE, Browne M, Moffat AJ, et al. Crack initiation processes in acrylic bone cement. *J Biomed Mater Res A* 2009; 89A: 1088–1097.
15. Coultrup OJ, Browne M, Hunt C, et al. Accounting for inclusions and voids allows the prediction of tensile fatigue life of bone cement. *J Biomech Eng* 2009; 131: 1–8.
16. Shearwood-Porter N, Browne M and Sinclair I. Micromechanical characterisation of failure in acrylic bone cement: the effect of barium sulphate agglomerates. *J Mech Behav Biomed Mater* 2012; 13: 85–92.
17. Liu C, Green SM, Watkins ND, et al. Some failure modes of four clinical bone cements. *Proc Inst Mech Eng H* 2001; 215: 359–366.
18. Sinnott-Jones PE, Browne M, Ludwig W, et al. Microtomography assessment of failure in acrylic bone cement. *Biomaterials* 2005; 26: 6460–6466.
19. Bhambri SK and Gilbertson LN. Micromechanism of fatigue crack initiation and propagation in bone cements. *J Biomed Mater Res* 1995; 29: 233–237.
20. Beaumont PW. Fracture processes in acrylic bone cement containing barium sulphate dispersions. *J Biomed Eng* 1979; 1: 147–152.
21. Topoleski LD, Ducheyne P and Cuckler JM. A fractography analysis of *in vivo* poly(methyl methacrylate) bone cement failure mechanisms. *J Biomed Mater Res* 1990; 24: 135–142.
22. Culleton P, Prendergast PJ and Taylor D. Fatigue failure in the cement mantle of an artificial hip joint. *Clin Mater* 1993; 12: 95–102.
23. Evans S. Fatigue crack propagation under variable amplitude loading in PMMA and bone cement. *J Mater Sci Mater Med* 2007; 18: 1711–1717.
24. Baleani M and Viceconti M. The effect of adding 10% of barium sulphate radiopacifier on the mechanical behaviour of acrylic bone cement. *Fatigu Fract Eng Mater Struct* 2011; 34: 374–382.
25. Ginebra MP, Albuixech L, Fernández-Barragán E, et al. Mechanical performance of acrylic bone cements containing different radiopacifying agents. *Biomaterials* 2002; 23: 1873–1882.
26. Freitag TA and Cannon SL. Fracture and fatigue characteristics of bone cements II. Fatigue. *J Biomed Mater Res* 1977; 11: 609–624.

27. Demian HW, Wey AC and Shalaby SW. Bone cement with exceptionally uniform dispersion of radiopacifier. In: *Trans 21st Ann Mtg, Soc Biomater*, San Francisco, CA, 1995, p.368.
28. Koole LH, Krufft MB, Colnot JM, et al. Studies on a new, all-polymeric radiopaque orthopaedic bone cement. In: *Trans 25th Ann Mtg, Soc Biomater*, Providence, RI, 1999, p.316.
29. Minari C, Cristofolini L, Baruffaldi F, et al. Radiopacity and fatigue characterization of a novel acrylic bone cement with sodium fluoride. *Artif Organs* 2000; 24: 751–757.
30. Bellare A, Gomoll A, Fitz W, et al. Using nanotechnology to improve the fatigue performance of acrylic bone cement. In: *Trans 47th Ann Mtg Orthop Res Soc*, San Francisco, CA, 2001, p. 182.
31. Bellare A, Turell M, Ganesam P, et al. Mechanisms of crack propagation in a conventional and nanocomposite bone cement. In: *Trans 48th Ann Mtg Orthop Res Soc*, Dallas, TX, 2002, p. 1067.
32. Evans S. Effects of porosity on the fatigue performance of polymethyl methacrylate bone cement: an analytical investigation. *Proc Inst Mech Eng H* 2006; 220: 1–10.
33. Shardlow DL, Stone MH, Ingham E, et al. Cement particles containing radio-opacifiers stimulate pro-osteolytic cytokine production from a human monocytic cell line. *J Bone Joint Surg Br Vol* 2003; 85-B: 900–905.
34. Lazarus M, Cuckler J, Schumacher H Jr, et al. Comparison of the inflammatory response to particulate polymethylmethacrylate debris with and without barium sulfate. *J Orthop Res* 1994; 12: 532–541.
35. Sabokbar A, Fujikawa Y, Murray DW, et al. Radiopaque agents in bone cement increase bone resorption. *J Bone Joint Surg Br Vol* 1997; 79-B: 129–134.
36. Wimhurst JA, Brooks RA and Rushton N. The effects of particulate bone cements at the bone-implant interface. *J Bone Joint Surg Br Vol* 2001; 83-B: 588–592. DOI: 10.1302/0301-620X.83B4.0830588.
37. Wang JS, Diaz J, Sabokbar A, et al. In vitro and in vivo biological responses to a novel radiopacifying agent for bone cement. *J R Soc Interface* 2005; 2: 71–78.
38. Khaled SMZ, Charpentier PA and Rizkalla AS. Synthesis and characterization of poly(methyl methacrylate)-based experimental bone cements reinforced with TiO<sub>2</sub>-SrO nanotubes. *Acta Biomater* 2010; 6: 3178–3186.
39. Ricker A, Liu-Snyder P and Webster TJ. The influence of nano MgO and BaSO<sub>4</sub> particle size additives on properties of PMMA bone cement. *Int J Nanomed* 2008; 3: 125–132.
40. Breusch SJ and Malchau H. *The well-cemented total hip arthroplasty: theory and practice*. Berlin: Springer, 2005.
41. Gupta R and Xie H. Nanoparticles in daily life: applications, toxicity and regulations. *J Environ Pathol Toxicol Oncol* 2018; 37: 209–230.
42. Basu B. Toughening of yttria-stabilised tetragonal zirconia ceramics. *Int Mater Rev* 2005; 50: 239–256.
43. Ellingsen JE. A study on the mechanism of protein adsorption to TiO<sub>2</sub>. *Biomaterials* 1991; 12: 593–596.
44. Wu W and Nancollas GH. Kinetics of heterogeneous nucleation of calcium phosphates on anatase and rutile surfaces. *J Colloid Interface Sci* 1998; 199: 206–211.
45. Mao C, Li H, Cui F, et al. Oriented growth of phosphates on polycrystalline titanium in a process mimicking biomineralization. *J Cryst Growth* 1999; 206: 308–321.
46. Gelest Inc. Silane coupling agents: connecting across boundaries, [www.gelest.com/wp-content/uploads/Goods-PDF-brochures-couplingagents.pdf](http://www.gelest.com/wp-content/uploads/Goods-PDF-brochures-couplingagents.pdf) (2006, accessed 26 April 2020).
47. Arkles B. Tailoring surfaces with silanes. *Chemtech* 1977; 7: 766–778.
48. Garoff H and Ansorge W. Improvements of DNA sequencing gels. *Anal Biochem* 1981; 115: 450–457.
49. Yerby SA, Paal AF, Young PM, et al. The effect of a silane coupling agent on the bond strength of bone cement and cobalt–chrome alloy. *J Biomed Mater Res* 2000; 49: 127–133.
50. May KB, Fox J, Razzoog ME, et al. Silane to enhance the bond between polymethyl methacrylate and titanium. *J Prosthet Dent* 1995; 73: 428–431.
51. ISO 5833: 2002. Implants for surgery: acrylic resin cements.
52. Ebramzadeh E, Sarmiento A, McKellop HA, et al. The cement mantle in total hip arthroplasty. analysis of long-term radiographic results. *J Bone Joint Surg Am* 1994; 76: 77–87.
53. BS EN 828: 2013. Adhesives. Wettability. Determination by measurement of contact angle and surface free energy of solid surface.
54. ISO 13586: 2000. Plastics: determination of fracture toughness (G<sub>IC</sub> and K<sub>IC</sub>). Linear elastic fracture mechanics (LEFM) approach.
55. Ayre WN, Denyer SP and Evans SL. Ageing and moisture uptake in polymethyl methacrylate (PMMA) bone cements. *J Mech Behav Biomed Mater* 2014; 32: 76–88.
56. ASTM E399 - 09e2. 2009. Standard test method for linear-elastic plane-strain fracture toughness of metallic materials.
57. ISO 23317: 2007. Implants for surgery - *In vitro* evaluation for apatite-forming ability of implant materials.
58. Kokubo T, Kushitani H, Sakka S, et al. Solutions able to reproduce *in vivo* surface-structure changes in bioactive glass-ceramic A-W. *J Biomed Mater Res* 1990; 24: 721–734.
59. Cen ISO/TS 80004-2:2017. Nanotechnologies – vocabulary. Part 2: Nano-objects.
60. Beutel J, Kundel HL and van Metter RL. *Handbook of medical imaging: physics and psychophysics*. Bellington: The International Society for Optical Instrumentation, 2000, p. 968.
61. Matinlinna JP, Özcan M, Lassila LVJ, et al. The effect of a 3-methacryloxypropyltrimethoxysilane and vinyltriisopropoxysilane blend and tris(3-trimethoxysilylpropyl)isocyanurate on the shear bond strength of composite resin to titanium metal. *Dent Mater* 2004; 20: 804–813.
62. Okada M, Inoue K, Irie M, et al. Resin adhesion strengths to zirconia ceramics after primer treatment with silane coupling monomer or oligomer. *Dent Mater J* 2017; 36: 600–605.

63. Mark JE. *Physical properties of polymers handbook*. New York: Springer, 2007.
64. Ebnesajjad S. *Handbook of adhesives and surface Preparation – technology, applications and manufacturing*. Oxford: Elsevier, 2011.
65. Weidenfeller B, Höfer M and Schilling FR. Thermal and electrical properties of magnetite filled polymers. *Compos Part A Appl Sci Manuf* 2002; 33: 1041–1053.
66. Weidenfeller B, Höfer M and Schilling FR. Thermal conductivity, thermal diffusivity, and specific heat capacity of particle filled polypropylene. *Compos Part A Appl Sci Manuf* 2004; 35: 423–429.
67. Chou PM and Mariatti M. The properties of polymethyl methacrylate (PMMA) bone cement filled with titania and hydroxyapatite fillers. *Polym Plast Technol Eng* 2010; 49: 1163–1171.
68. Rodríguez H and Piña M. Bone cement reinforced with zirconium oxide particles. In: Narayan R, Kumta P and Wagner W (eds) *Advances in biomedical and biomimetic materials*. Hoboken: John Wiley & Sons, 2009, pp.39–46.
69. Matos AC, Ribeiro IAC, Guedes RC, et al. Key-properties outlook of a levofloxacin-loaded acrylic bone cement with improved antibiotic delivery. *Int J Pharm* 2015; 485: 317–328.
70. Ozcan C and Hasirci N. Evaluation of surface free energy for PMMA films. *J Appl Polym Sci* 2008; 108: 438–446.
71. Pinto JF, Buckton G and Newton JM. A relationship between surface free energy and polarity data and some physical properties of spheroids. *Int J Pharm* 1995; 118: 95–101.
72. Gonzalez-Martin ML, Labajos-Broncano L, Janczuk B, et al. Wettability and surface free energy of zirconia ceramics and their constituents. *J Mater Sci* 1999; 34: 5923–5926.
73. Fukuda C, Goto K, Imamura M, et al. Bioactive bone cement with a low content of titania particles without postsilanization: effect of filler content on osteoconductivity, mechanical properties, and handling characteristics. *J Biomed Mater Res* 2010; 95B: 407–413.
74. Fukuda C, Goto K, Imamura M, et al. Bone bonding ability and handling properties of titania-polymethylmethacrylate (PMMA) composite bioactive bone cement modified with unique PMMA powder. *Acta Biomater* 2011; 7: 3595–3600.
75. Goto K, Tamura J, Shinzato S, et al. Bioactive bone cements containing nano-sized titania particles for use as bone substitutes. *Biomaterials* 2005; 26: 6496–6505.
76. Li F, Zhao D, Luo Q, et al. Research on surface-modification of nano-TiO<sub>2</sub> by span 60. *J Ceram Proc Res* 2008; 9: 398–400.
77. Janssen D, Stolk J and Verdonchot N. Why would cement porosity reduction be clinically irrelevant, while experimental data show the contrary. *J Orthop Res* 2005; 23: 691–697.
78. Gillani R, Ercan B, Qiao A, et al. Nanofunctionalized zirconia and barium sulfate particles as bone cement additives. *Int J Nanomed* 2009; 5: 1–11.
79. Uchida M, Kim H-M, Kokubo T, et al. Structural dependence of apatite formation on titania gels in a simulated body fluid. *J Biomed Mater Res A* 2003; 64A: 164–170.
80. Busscher HJ, de Jong HP and Arends J. Surface free energies of hydroxyapatite, fluorapatite and calcium fluoride. *Mater Chem Phys* 1987; 17: 553–558.
81. Czekanska EM, Stoddart MJ, Richards RG, et al. In search of an osteoblast cell model for in vitro research. *Eur Cell Mater* 2012; 24: 1–17.
82. Wei J, Igarashi T, Okumori N, et al. Influence of surface wettability on competitive protein adsorption and initial attachment of osteoblasts. *Biomed Mater* 2009; 4: 045002–042009.
83. Dupraz AMP, vd Meer SAT, De Wijn JR, et al. Biocompatibility screening of silane-treated hydroxyapatite powders, for use as filler in resorbable composites. *J Mater Sci Mater Med* 1996; 7: 731–738.
84. Goto K, Hashimoto M, Takadama H, et al. Mechanical, setting, and biological properties of bone cements containing micron-sized titania particles. *J Mater Sci Mater Med* 2008; 19: 1009–1016.